Myeloid-derived suppressor cells: paradoxical roles in infection and immunity.

Jun Dai, Mohamed El Gazzar, Guang Y Li, Jonathan P Moorman, Zhi Q Yao
Author Information
  1. Jun Dai: Center for Inflammation, Infectious Diseases and Immunity, Quillen College of Medicine, East Tennessee State University, Johnson City, Tenn., USA.

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature suppressor cells that are generated due to aberrant myelopoiesis under pathological conditions. Although MDSCs have been recognized for more than 20 years under the guise of different monikers, these particular populations of myeloid cells gained more attention recently due to their immunosuppressive properties, which halt host immune responses to growing cancers or overwhelming infections. While MDSCs may contribute to immune homeostasis after infection or tissue injury by limiting excessive inflammatory processes, their expansion may be at the expense of pathogen elimination and thus may lead to disease persistence. Therefore, MDSCs may be either damaging or obliging to the host by attenuating, for example, antitumor or anti-infectious immune responses. In this review, we recapitulate the biological and immunological aspects of MDSCs, including their generation, distribution, trafficking and the factors involved in their activation, expansion, suppressive functions, and interplay between MDSCs and regulatory T cells, with a focus on the perspectives of infection and inflammation.

References

  1. Cancer Res. 2010 Jan 1;70(1):99-108 [PMID: 19996287]
  2. J Clin Oncol. 2007 Jun 20;25(18):2546-53 [PMID: 17577033]
  3. J Immunol. 2007 Oct 15;179(8):5228-37 [PMID: 17911608]
  4. Nat Med. 2007 Jul;13(7):828-35 [PMID: 17603493]
  5. Cancer Immunol Immunother. 2008 Oct;57(10):1493-504 [PMID: 18322683]
  6. J Immunol. 2001 Jun 15;166(12):7504-13 [PMID: 11390504]
  7. Cancer Res. 2004 Sep 1;64(17):6337-43 [PMID: 15342423]
  8. J Immunol. 2005 May 15;174(10):6095-104 [PMID: 15879104]
  9. Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17686-91 [PMID: 20861446]
  10. Cancer Res. 2006 Sep 15;66(18):9299-307 [PMID: 16982775]
  11. J Exp Med. 2007 Jun 11;204(6):1463-74 [PMID: 17548519]
  12. J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 [PMID: 19572148]
  13. Curr Cancer Drug Targets. 2007 Feb;7(1):31-40 [PMID: 17305476]
  14. AIDS. 2012 Jul 31;26(12):F31-7 [PMID: 22526518]
  15. J Crit Care. 2012 Aug;27(4):415.e1-11 [PMID: 22079179]
  16. J Leukoc Biol. 2008 May;83(5):1136-44 [PMID: 18285406]
  17. J Immunol. 2005 Apr 15;174(8):4880-91 [PMID: 15814715]
  18. J Immunol. 2007 Jul 15;179(2):977-83 [PMID: 17617589]
  19. Eur J Immunol. 2011 Mar;41(3):749-59 [PMID: 21287554]
  20. Mol Ther. 2009 Mar;17(3):508-15 [PMID: 19127252]
  21. PLoS One. 2010;5(3):e9852 [PMID: 20352042]
  22. J Clin Invest. 2011 Oct;121(10):4015-29 [PMID: 21911941]
  23. Eur J Immunol. 2014 Jan;44(1):184-94 [PMID: 24166778]
  24. Nat Med. 2004 Sep;10(9):942-9 [PMID: 15322536]
  25. Cancer Res. 2004 Aug 15;64(16):5839-49 [PMID: 15313928]
  26. PLoS One. 2011;6(11):e27690 [PMID: 22110722]
  27. Curr Med Chem. 2013;20(11):1437-44 [PMID: 23409714]
  28. Nat Rev Immunol. 2007 Aug;7(8):650-4 [PMID: 17653127]
  29. Nat Rev Immunol. 2012 Apr;12(4):253-68 [PMID: 22437938]
  30. J Virol. 2013 Feb;87(3):1477-90 [PMID: 23152536]
  31. Cancer Res. 2009 Feb 15;69(4):1553-60 [PMID: 19201693]
  32. Shock. 2001 Aug;16(2):83-96 [PMID: 11508871]
  33. Cancer Res. 2012 Feb 15;72(4):928-38 [PMID: 22237629]
  34. Cancer Res. 1987 Jan 1;47(1):100-5 [PMID: 2947676]
  35. Cancer Res. 2009 Jul 1;69(13):5514-21 [PMID: 19549903]
  36. Cancer Res. 2006 Jan 15;66(2):1123-31 [PMID: 16424049]
  37. Cell Transplant. 2011;20(6):941-54 [PMID: 21054938]
  38. Mol Med. 2011 Mar-Apr;17(3-4):281-92 [PMID: 21085745]
  39. Crit Care. 2006;10(5):233 [PMID: 17044947]
  40. Curr Opin Infect Dis. 2012 Jun;25(3):321-7 [PMID: 22421753]
  41. Trends Immunol. 2002 Nov;23(11):549-55 [PMID: 12401408]
  42. Cancer Res. 2005 Apr 15;65(8):3044-8 [PMID: 15833831]
  43. Immunology. 2013 Feb;138(2):105-15 [PMID: 23216602]
  44. J Exp Med. 2010 Oct 25;207(11):2439-53 [PMID: 20876310]
  45. Nat Rev Immunol. 2009 Mar;9(3):162-74 [PMID: 19197294]
  46. Blood. 2008 Apr 15;111(8):4233-44 [PMID: 18272812]
  47. Proc Natl Acad Sci U S A. 2012 Nov 6;109(45):E3101-10 [PMID: 23071313]
  48. Cancer Res. 2009 Jun 1;69(11):4800-9 [PMID: 19458073]
  49. J Immunol. 2008 Sep 1;181(5):3291-300 [PMID: 18714001]
  50. J Natl Cancer Inst. 1984 Jul;73(1):249-55 [PMID: 6610791]
  51. J Infect Dis. 2014 Feb 1;209(3):441-51 [PMID: 23999600]
  52. Eur J Immunol. 2010 Jan;40(1):22-35 [PMID: 19941314]
  53. J Leukoc Biol. 2005 Aug;78(2):325-37 [PMID: 15817707]
  54. J Mol Cell Biol. 2013 Jun;5(3):207-9 [PMID: 23532593]
  55. Eur J Immunol. 2009 Oct;39(10):2670-2 [PMID: 19757440]
  56. Crit Care Med. 2013 Mar;41(3):820-32 [PMID: 23348516]
  57. J Exp Med. 2009 Jun 8;206(6):1327-37 [PMID: 19451266]
  58. Science. 2008 Jan 11;319(5860):154-6 [PMID: 18187637]
  59. J Exp Med. 2011 Sep 26;208(10):1949-62 [PMID: 21930770]
  60. Proc Natl Acad Sci U S A. 1995 Jul 3;92(14):6254-8 [PMID: 7603979]
  61. J Immunol. 2008 Oct 15;181(8):5791-802 [PMID: 18832739]
  62. Int J Cancer. 2014 Apr 15;134(8):1810-22 [PMID: 24150772]
  63. Nat Rev Immunol. 2013 Dec;13(12):862-74 [PMID: 24232462]
  64. J Leukoc Biol. 2007 May;81(5):1205-12 [PMID: 17307863]
  65. Semin Cancer Biol. 2012 Aug;22(4):275-81 [PMID: 22313874]
  66. N Engl J Med. 2003 Jan 9;348(2):138-50 [PMID: 12519925]
  67. J Immunol. 2006 Feb 15;176(4):2085-94 [PMID: 16455964]
  68. Cancer Res. 2004 Mar 15;64(6):2205-11 [PMID: 15026364]
  69. Hepatology. 2012 Feb;55(2):343-53 [PMID: 21953144]
  70. Cancer Res. 2001 Jun 15;61(12):4756-60 [PMID: 11406548]
  71. J Immunol. 2009 Apr 15;182(8):4499-506 [PMID: 19342621]
  72. Infect Immun. 2012 Jun;80(6):2026-34 [PMID: 22451518]
  73. Immunity. 2013 Feb 21;38(2):309-21 [PMID: 23438822]
  74. J Transl Med. 2013;11:16 [PMID: 23320561]
  75. J Immunol. 2006 Oct 1;177(7):4763-72 [PMID: 16982917]
  76. Cancer Res. 2010 Jun 1;70(11):4335-45 [PMID: 20484028]
  77. J Immunol. 2012 May 1;188(9):4209-16 [PMID: 22450806]
  78. Eur J Immunol. 2005 Dec;35(12):3533-44 [PMID: 16331707]
  79. Eur J Immunol. 1997 Feb;27(2):509-14 [PMID: 9045924]
  80. J Immunol. 2005 Jan 15;174(2):636-45 [PMID: 15634881]
  81. J Immunol. 2004 Jan 15;172(2):989-99 [PMID: 14707072]
  82. Cancer Res. 2006 Jul 1;66(13):6807-15 [PMID: 16818658]
  83. J Exp Med. 2011 Dec 19;208(13):2581-90 [PMID: 22110166]
  84. Cancer Res. 2004 Feb 1;64(3):1130-9 [PMID: 14871848]
  85. Gastroenterology. 2008 Jul;135(1):234-43 [PMID: 18485901]
  86. Immunology. 2009 Sep;128(1):141-9 [PMID: 19689743]
  87. Trends Immunol. 2009 Oct;30(10):475-87 [PMID: 19781994]
  88. Biomed Res. 2009 Feb;30(1):7-15 [PMID: 19265258]
  89. Oncoimmunology. 2012 Dec 1;1(9):1650-1651 [PMID: 23264925]
  90. Immunol Rev. 2013 Sep;255(1):210-21 [PMID: 23947357]
  91. Shock. 2010 Sep;34 Suppl 1:15-21 [PMID: 20714263]
  92. Immunity. 2012 Mar 23;36(3):491-501 [PMID: 22406268]
  93. Eur J Immunol. 2009 Oct;39(10):2865-76 [PMID: 19637228]
  94. Oncoimmunology. 2013 Jun 1;2(6):e24441 [PMID: 23894703]
  95. Shock. 2004 May;21(5):415-25 [PMID: 15087817]
  96. J Immunol. 2006 Jan 1;176(1):284-90 [PMID: 16365420]
  97. J Exp Med. 2010 Jul 5;207(7):1453-64 [PMID: 20530204]
  98. Am J Transplant. 2013 Dec;13(12):3123-31 [PMID: 24103111]
  99. Cancer Sci. 2007 Jun;98(6):882-9 [PMID: 17433038]
  100. AIDS. 2012 Jul 31;26(12):1567-9 [PMID: 22810370]
  101. Nat Immunol. 2009 Nov;10(11):1178-84 [PMID: 19783988]
  102. Nat Med. 2014 Jan;20(1):69-74 [PMID: 24317118]

Grants

  1. R01AI114748/NIAID NIH HHS
  2. R01 AI114748/NIAID NIH HHS
  3. R01DK093526/NIDDK NIH HHS
  4. R15 AG050456/NIA NIH HHS
  5. R01 DK093526/NIDDK NIH HHS

MeSH Term

Animals
Cell Communication
Homeostasis
Humans
Immune Tolerance
Immunity
Infections
Myeloid Cells
Myelopoiesis
T-Lymphocytes, Regulatory

Word Cloud

Created with Highcharts 10.0.0MDSCscellsmaysuppressorimmuneinfectionMyeloid-derivedduehostresponsesexpansionheterogeneouspopulationimmaturegeneratedaberrantmyelopoiesispathologicalconditionsAlthoughrecognized20yearsguisedifferentmonikersparticularpopulationsmyeloidgainedattentionrecentlyimmunosuppressivepropertieshaltgrowingcancersoverwhelminginfectionscontributehomeostasistissueinjurylimitingexcessiveinflammatoryprocessesexpensepathogeneliminationthusleaddiseasepersistenceThereforeeitherdamagingobligingattenuatingexampleantitumoranti-infectiousreviewrecapitulatebiologicalimmunologicalaspectsincludinggenerationdistributiontraffickingfactorsinvolvedactivationsuppressivefunctionsinterplayregulatoryTfocusperspectivesinflammationcells:paradoxicalrolesimmunity

Similar Articles

Cited By